<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219648">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224562</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <secondary_id>INSERM</secondary_id>
    <nct_id>NCT00224562</nct_id>
  </id_info>
  <brief_title>The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists</brief_title>
  <official_title>The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <brief_summary>
    <textblock>
      The RATIO registry is a French registry designed by a multidisciplinary group to collect
      data on opportunistic and severe bacterial infections and lymphoma in patients treated with
      TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in
      metropolitan France participate in the RATIO registry. All diagnosis are retained after
      validation by 2 qualified infectious disease or haematologist physicians (on the basis of
      the standardized case report form, the hospitalisation summary, and the microbiological and
      radiological results). Risk factors for developing these conditions when treated by TNF-a
      antagonists will be identified in a case control study. Incidence of these diseases will be
      calculated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2004</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control, Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Crohn's Disease</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF-alpha antagonists</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for cases:

          -  past or current treatement with TNF-a antagonists

          -  either lymphoma severe bacterial infection opportunistic infection

        Inclusion Criteria for controls:

          -  matched with cases by gender, age (+/- 5 years), underlying disease (rheumatoid
             arthritis, ankylosing spondylitis, Crohn's disease, or psoriasis)

          -  past or current treatement with TNF-a antagonists

          -  no lymphoma, severe bacterial infection, opportunistic infection (same as case)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Mariette, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Salmon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Lemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence TUBACH, MD</last_name>
    <phone>01 40 25 62 51</phone>
    <email>florence.tubach@bch.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>All French departments of rheumatology, internal medicine, gastro-enterology, dermatology, infectious diseases, intensive care unit, oncology and haematology, paediatrics and chest medicine</name>
      <address>
        <city>All Cities</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Tubach, MD</last_name>
      <phone>01 40 25 62 51</phone>
      <email>florence.tubach@bch.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2004</verification_date>
  <lastchanged_date>October 25, 2005</lastchanged_date>
  <firstreceived_date>September 14, 2005</firstreceived_date>
  <keyword>TNF alpha antagonists</keyword>
  <keyword>infections</keyword>
  <keyword>lymphoma</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
